Profile data is unavailable for this security.
About the company
Conduit Pharmaceuticals, Inc. is a disease agnostic life science company. The Company is engaged in the development and commercialization of clinical assets to address the unmet medical needs of patients. The Company’s licensed clinical assets are focused on idiopathic male infertility and autoimmune diseases or immunodeficient conditions like uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. The Company’s asset pipeline includes AZD1656 (a Glucokinase Activator), and AZD5904 (a Myeloperoxidase Inhibitor). AZD1656 is a glucokinase activator used in diabetes mellitus. It is used as a treatment option for Hashimoto’s Thyroiditis (HT and Graves’ disease, including investigating any negative side effects of the use of AZD1656 as compared with treatment options for Hashimoto’s Thyroiditis and Graves’ disease. AZD5904 includes a potent, irreversible inhibitor of human myeloperoxidase (MPO), that has the potential to treat Idiopathic Male Infertility (IMI).
- Revenue in USD (TTM)--
- Net income in USD--
- Incorporated2021
- Employees--
- LocationConduit Pharmaceuticals Inc4995 Murphy Canyon Road, Suite 300SAN DIEGO 92123United StatesUSA
- Phone+1 (760) 471-8536
- Fax+1 (302) 655-5049
- Websitehttps://www.conduitpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INmune Bio Inc | 131.00k | -34.50m | 200.00m | 11.00 | -- | 6.25 | -- | 1,526.72 | -1.92 | -1.92 | 0.0073 | 1.62 | 0.0022 | -- | 0.0535 | 11,909.09 | -57.11 | -37.82 | -74.12 | -41.86 | -- | -- | -26,333.59 | -14,901.03 | -- | -16.97 | 0.2044 | -- | -58.56 | -- | -9.92 | -- | -- | -- |
| Compass Therapeutics Inc. | 0.00 | -45.44m | 202.26m | 32.00 | -- | 1.29 | -- | -- | -0.3513 | -0.3513 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -26.03 | -41.75 | -27.21 | -46.41 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.33 | -- | -56.91 | -- |
| Generation Bio Co | 9.96m | -169.06m | 204.24m | 174.00 | -- | 1.55 | -- | 20.50 | -2.56 | -2.56 | 0.1509 | 1.99 | 0.0278 | -- | 10.98 | 57,258.62 | -47.14 | -36.96 | -50.75 | -39.21 | -- | -- | -1,696.87 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -55.94m | 204.27m | 51.00 | -- | 0.7796 | -- | -- | -1.05 | -1.05 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | -22.89 | -- | -23.72 | -- | -- | -- | -- | -- | -- | -- | 0.1034 | -- | -- | -- | -22.20 | -- | -- | -- |
| Scilex Holding Co | 47.05m | -160.60m | 204.74m | 106.00 | -- | -- | -- | 4.35 | -1.28 | -1.28 | 0.3905 | -1.79 | 0.5307 | 5.53 | 1.92 | 448,047.60 | -121.78 | -- | -- | -- | 66.14 | -- | -229.47 | -- | 0.1356 | -12.49 | -- | -- | 22.90 | -- | -614.67 | -- | -- | -- |
| TriSalus Life Sciences Inc | 21.98m | -68.07m | 205.32m | 112.00 | -- | -- | -- | 9.34 | -2.09 | -2.09 | 0.7291 | -1.31 | 1.17 | 1.26 | 7.49 | 196,276.80 | -339.18 | -- | -11,196.50 | -- | 86.74 | -- | -291.08 | -- | 0.714 | -16.82 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| AVITA Medical Inc | 50.70m | -44.82m | 208.98m | 207.00 | -- | 6.41 | -- | 4.12 | -1.76 | -1.76 | 1.99 | 1.26 | 0.5336 | 1.48 | 8.39 | 244,913.00 | -47.18 | -- | -53.79 | -- | 85.43 | -- | -88.41 | -- | 6.64 | -19.61 | 0.5591 | -- | 45.68 | -- | -32.69 | -- | -- | -- |
| Renovaro Inc | 0.00 | -53.93m | 209.46m | 11.00 | -- | 1.24 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 209.68m | -- | -- | -- | -- | -- | -- | -- | -- | -0.042 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Elevation Oncology Inc | 0.00 | -39.35m | 209.81m | 29.00 | -- | 2.62 | -- | -- | -1.03 | -1.03 | 0.00 | 1.47 | 0.00 | -- | -- | 0.00 | -42.35 | -- | -46.30 | -- | -- | -- | -- | -- | -- | -12.50 | 0.2889 | -- | -- | -- | 51.93 | -- | -- | -- |
| Werewolf Therapeutics Inc | 16.22m | -41.58m | 212.06m | 46.00 | -- | 1.80 | -- | 13.07 | -1.09 | -1.09 | 0.4343 | 2.72 | 0.087 | -- | 4.61 | 345,127.70 | -22.31 | -- | -25.22 | -- | -- | -- | -256.33 | -- | -- | -- | 0.2511 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| Ovid Therapeutics Inc | 473.53k | -50.68m | 212.83m | 40.00 | -- | 2.71 | -- | 449.46 | -0.7174 | -0.7174 | 0.0067 | 1.11 | 0.0034 | -- | -- | 11,838.25 | -36.86 | -20.78 | -39.08 | -23.27 | -- | -- | -10,701.91 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| G1 Therapeutics Inc | 84.04m | -30.59m | 213.83m | 100.00 | -- | 7.70 | -- | 2.54 | -0.6146 | -0.6146 | 1.55 | 0.531 | 0.6367 | 0.4852 | 6.07 | 840,410.00 | -23.18 | -47.06 | -30.95 | -52.64 | 91.89 | -- | -36.40 | -268.59 | 2.55 | -3.31 | 0.6084 | -- | 60.84 | -- | 67.49 | -- | -- | -- |
| Eliem Therapeutics Inc | 0.00 | -14.53m | 215.57m | 9.00 | -- | 1.93 | -- | -- | -0.5347 | -0.5347 | 0.00 | 3.84 | 0.00 | -- | -- | 0.00 | -12.55 | -- | -13.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.38 | -- | -- | -- |
| Coherus Biosciences Inc | 301.87m | -59.29m | 219.13m | 249.00 | -- | -- | -- | 0.7259 | -0.7801 | -0.7801 | 2.86 | -0.7211 | 0.5178 | 3.17 | 1.71 | 986,506.60 | -10.17 | -21.43 | -23.51 | -29.32 | 41.46 | 79.01 | -19.64 | -36.56 | 1.05 | -3.87 | 1.21 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
Data as of May 24 2024. Currency figures normalised to Conduit Pharmaceuticals Inc's reporting currency: US Dollar USD
2.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Barclays Bank Plc (Private Banking)as of 31 Mar 2024 | 804.29k | 1.09% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 202.93k | 0.28% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 153.36k | 0.21% |
| Geode Capital Management LLCas of 31 Mar 2024 | 138.94k | 0.19% |
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Mar 2024 | 68.55k | 0.09% |
| Marshall Wace LLPas of 31 Mar 2024 | 61.95k | 0.08% |
| Qube Research & Technologies Ltd.as of 31 Mar 2024 | 40.99k | 0.06% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 26.83k | 0.04% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 21.79k | 0.03% |
| Y-Intercept (Hong Kong) Ltd.as of 31 Mar 2024 | 19.27k | 0.03% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
